Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Golo Ahlenstiel

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Immune Network|November 8, 2013
The natural killer cell response to HCV infectionGolo Ahlenstiel
Hepatology (Baltimore, Md.)|February 22, 2005
Hepatitis C virus and the threshold of natural killer cell inhibitionGolo Ahlenstiel, Barbara Rehermann
Chinese Clinical Oncology|September 11, 2023
Pembrolizumab: a potential game-changer in the treatment of advanced hepatocellular carcinomaDmitrii Shek, Golo Ahlenstiel
Immunity|March 12, 2025
Immo-bile-izing CD8<sup>+</sup> T cell anti-tumor immunityScott A Read, Golo Ahlenstiel
Cells|September 23, 2022
Reprogramming-Evolving Path to Functional Surrogate β-CellsEric Kalo, Scott Read, Golo Ahlenstiel
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|April 24, 2019
Interferon Lambda and Liver FibrosisMohammed Eslam, Golo Ahlenstiel, Jacob George
World Journal of Gastroenterology|December 24, 2013
Ophthalmologic complications of antiviral therapy in hepatitis C treatmentRoderick O'Day, Mark C Gillies, Golo Ahlenstiel
Antiviral Therapy|November 29, 2012
Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?Golo Ahlenstiel, David R Booth, Jacob George
Journal of Gastroenterology|July 17, 2010
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practiceGolo Ahlenstiel, David R Booth, Jacob George
Genome Medicine|December 28, 2012
Pharmacogenomics of hepatitis C infections: personalizing therapyDavid R Booth, Golo Ahlenstiel, Jacob George
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Immune Network|November 8, 2013
The natural killer cell response to HCV infectionGolo Ahlenstiel
Hepatology (Baltimore, Md.)|February 22, 2005
Hepatitis C virus and the threshold of natural killer cell inhibitionGolo Ahlenstiel, Barbara Rehermann
Chinese Clinical Oncology|September 11, 2023
Pembrolizumab: a potential game-changer in the treatment of advanced hepatocellular carcinomaDmitrii Shek, Golo Ahlenstiel
Immunity|March 12, 2025
Immo-bile-izing CD8<sup>+</sup> T cell anti-tumor immunityScott A Read, Golo Ahlenstiel
Cells|September 23, 2022
Reprogramming-Evolving Path to Functional Surrogate β-CellsEric Kalo, Scott Read, Golo Ahlenstiel
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|April 24, 2019
Interferon Lambda and Liver FibrosisMohammed Eslam, Golo Ahlenstiel, Jacob George
World Journal of Gastroenterology|December 24, 2013
Ophthalmologic complications of antiviral therapy in hepatitis C treatmentRoderick O'Day, Mark C Gillies, Golo Ahlenstiel
Antiviral Therapy|November 29, 2012
Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?Golo Ahlenstiel, David R Booth, Jacob George
Journal of Gastroenterology|July 17, 2010
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practiceGolo Ahlenstiel, David R Booth, Jacob George
Genome Medicine|December 28, 2012
Pharmacogenomics of hepatitis C infections: personalizing therapyDavid R Booth, Golo Ahlenstiel, Jacob George
Pageof 13